222 related articles for article (PubMed ID: 16213533)
21. Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.
Riley AP; Groer CE; Young D; Ewald AW; Kivell BM; Prisinzano TE
J Med Chem; 2014 Dec; 57(24):10464-75. PubMed ID: 25426797
[TBL] [Abstract][Full Text] [Related]
22. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
Harding WW; Schmidt M; Tidgewell K; Kannan P; Holden KG; Gilmour B; Navarro H; Rothman RB; Prisinzano TE
J Nat Prod; 2006 Jan; 69(1):107-12. PubMed ID: 16441078
[TBL] [Abstract][Full Text] [Related]
23. Analytical investigation of legal high products containing Salvia divinorum traded in smartshops and internet.
Xavier Moreira F; Carvalho F; de Lourdes Bastos M; Guedes de Pinho P
Forensic Sci Int; 2014 Sep; 242():255-260. PubMed ID: 25093918
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.
Baker LE; Panos JJ; Killinger BA; Peet MM; Bell LM; Haliw LA; Walker SL
Psychopharmacology (Berl); 2009 Apr; 203(2):203-11. PubMed ID: 19153716
[TBL] [Abstract][Full Text] [Related]
25. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
Sheffler DJ; Roth BL
Trends Pharmacol Sci; 2003 Mar; 24(3):107-9. PubMed ID: 12628350
[TBL] [Abstract][Full Text] [Related]
26. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
Simpson DS; Katavic PL; Lozama A; Harding WW; Parrish D; Deschamps JR; Dersch CM; Partilla JS; Rothman RB; Navarro H; Prisinzano TE
J Med Chem; 2007 Jul; 50(15):3596-603. PubMed ID: 17580847
[TBL] [Abstract][Full Text] [Related]
27. The subjective experience of acute, experimentally-induced Salvia divinorum inebriation.
Addy PH; Garcia-Romeu A; Metzger M; Wade J
J Psychopharmacol; 2015 Apr; 29(4):426-35. PubMed ID: 25691501
[TBL] [Abstract][Full Text] [Related]
28. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.
Fichna J; Schicho R; Janecka A; Zjawiony JK; Storr M
Drug News Perspect; 2009 Sep; 22(7):383-92. PubMed ID: 19890495
[TBL] [Abstract][Full Text] [Related]
29. Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland.
Giroud C; Felber F; Augsburger M; Horisberger B; Rivier L; Mangin P
Forensic Sci Int; 2000 Aug; 112(2-3):143-50. PubMed ID: 10940599
[TBL] [Abstract][Full Text] [Related]
30. The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series.
El-Khoury J; Sahakian N
J Psychoactive Drugs; 2015; 47(4):286-92. PubMed ID: 26317561
[TBL] [Abstract][Full Text] [Related]
31. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.
Grundmann O; Phipps SM; Zadezensky I; Butterweck V
Planta Med; 2007 Aug; 73(10):1039-46. PubMed ID: 17628834
[TBL] [Abstract][Full Text] [Related]
32. Acute and post-acute behavioral and psychological effects of salvinorin A in humans.
Addy PH
Psychopharmacology (Berl); 2012 Mar; 220(1):195-204. PubMed ID: 21901316
[TBL] [Abstract][Full Text] [Related]
33. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.
Killinger BA; Peet MM; Baker LE
Pharmacol Biochem Behav; 2010 Sep; 96(3):260-5. PubMed ID: 20493209
[TBL] [Abstract][Full Text] [Related]
34. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.
Lee DY; Ma Z; Liu-Chen LY; Wang Y; Chen Y; Carlezon WA; Cohen B
Bioorg Med Chem; 2005 Oct; 13(19):5635-9. PubMed ID: 16084728
[TBL] [Abstract][Full Text] [Related]
35. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
[TBL] [Abstract][Full Text] [Related]
36. Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats.
Braida D; Donzelli A; Martucci R; Capurro V; Sala M
Int J Toxicol; 2011 Dec; 30(6):650-61. PubMed ID: 21960665
[TBL] [Abstract][Full Text] [Related]
37. [Authentication and ultra performance liquid chromatography (UPLC)/MS analysis of magic mint, Salvia divinorum and its related plants].
Maruyama T; Kamakura H; Kikura-Hanajiri R; Goda Y
Yakugaku Zasshi; 2008 Jan; 128(1):179-83. PubMed ID: 18176071
[TBL] [Abstract][Full Text] [Related]
38. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry.
Medana C; Massolino C; Pazzi M; Baiocchi C
Rapid Commun Mass Spectrom; 2006; 20(2):131-6. PubMed ID: 16331747
[TBL] [Abstract][Full Text] [Related]
39. Salvia divinorum: exposures reported to a statewide poison control system over 10 years.
Vohra R; Seefeld A; Cantrell FL; Clark RF
J Emerg Med; 2011 Jun; 40(6):643-50. PubMed ID: 19765944
[TBL] [Abstract][Full Text] [Related]
40. Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
Polepally PR; White K; Vardy E; Roth BL; Ferreira D; Zjawiony JK
Bioorg Med Chem Lett; 2013 May; 23(10):2860-2. PubMed ID: 23587424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
